New HIV drug MK-4646 put through safety check in healthy volunteers
NCT ID NCT07532304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a new experimental HIV drug, MK-4646, changes the levels of standard HIV medications (BIC/FTC/TAF and dolutegravir) in the blood. It involves 16 healthy volunteers and focuses on safety and drug interactions, not treatment. The results will help guide future studies in people living with HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-4646
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pinnacle Research Group ( Site 0001)
Anniston, Alabama, 36207, United States